Open AccessPreliminary Study of Chemoradiotherapy Using Modified Docetaxel, Cis‐diaminodichloroplatinum, and 5‐Fluorouracil for Sinonasal Squamous Cell Carcinoma
Author(s) -
Katagiri Katsunori,
Shiga Kiyoto,
Saito Daisuke,
Oikawa Shinichi,
Ikeda Aya,
Tsuchida Kodai,
Miyaguchi Jun,
Kusaka Takahiro,
Sariishi Takumi,
Ariga Hisanori
Publication year - 2021
Publication title -
oto open
Language(s) - English
Resource type - Journals
ISSN - 2473-974X
DOI - 10.1177/2473974x211045298
Subject(s) - docetaxel , medicine , concomitant , neutropenia , leukopenia , regimen , fluorouracil , chemoradiotherapy , febrile neutropenia , gastroenterology , chemotherapy , surgery , oncology
Objective To examine the safety and efficacy of concomitant chemoradiotherapy using a modified TPF regimen (docetaxel + cisplatin + 5‐fluorouracil) in patients with advanced sinonasal squamous cell carcinoma (SNSCC). Study Design Retrospective study. Setting Tertiary center (university hospital). Methods Seven patients with previously untreated T3‐T4 SNSCC were enrolled. They underwent radiotherapy once daily (total dose, 70 Gy) with 2 courses of concomitant 120‐hour infusion of 5‐fluorouracil (600 mg/m 2 /d), docetaxel (50 mg/m 2 , day 2), and cisplatin (60 mg/m 2 , day 2) Results Grade 4 leukopenia, grade 4 neutropenia, and grade 3 lymphopenia were observed in 1, 3, and 4 patients, respectively. Grade 4 creatinine elevation was observed in 1 patient. However, other grade 3 or 4 adverse events were not common. Complete response was obtained in all patients. At 60 months there was 85.7% disease‐free survival and 100% overall. Conclusion Concomitant chemoradiotherapy with a modified TPF regimen may be feasible and effective in patients with advanced SNSCC.